DK1622908T3 - Xanthin-derivater som A2B adenosin-receptor-antagonister - Google Patents

Xanthin-derivater som A2B adenosin-receptor-antagonister

Info

Publication number
DK1622908T3
DK1622908T3 DK03817096T DK03817096T DK1622908T3 DK 1622908 T3 DK1622908 T3 DK 1622908T3 DK 03817096 T DK03817096 T DK 03817096T DK 03817096 T DK03817096 T DK 03817096T DK 1622908 T3 DK1622908 T3 DK 1622908T3
Authority
DK
Denmark
Prior art keywords
receptor antagonists
adenosine receptor
xanthine derivatives
xanthine
derivatives
Prior art date
Application number
DK03817096T
Other languages
English (en)
Inventor
Rao Kalla
Thao Perry
Elfatih Elzein
Vaibhav Varkhedkar
Xiaofen Li
Prabha Ibrahim
Venkata Palle
Dengming Xiao
Jeff Zablocki
Original Assignee
Cv Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics Inc filed Critical Cv Therapeutics Inc
Application granted granted Critical
Publication of DK1622908T3 publication Critical patent/DK1622908T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DK03817096T 2003-05-06 2003-05-06 Xanthin-derivater som A2B adenosin-receptor-antagonister DK1622908T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/014085 WO2004106337A1 (en) 2003-05-06 2003-05-06 Xanthine derivatives as a2b adenosine receptor antagonists

Publications (1)

Publication Number Publication Date
DK1622908T3 true DK1622908T3 (da) 2008-11-17

Family

ID=33488737

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03817096T DK1622908T3 (da) 2003-05-06 2003-05-06 Xanthin-derivater som A2B adenosin-receptor-antagonister

Country Status (16)

Country Link
EP (1) EP1622908B1 (da)
JP (1) JP2006515316A (da)
CN (1) CN100590125C (da)
AT (1) ATE403656T1 (da)
AU (1) AU2003249604B2 (da)
CA (1) CA2524778C (da)
CY (1) CY1108457T1 (da)
DE (1) DE60322748D1 (da)
DK (1) DK1622908T3 (da)
ES (1) ES2311759T3 (da)
HK (1) HK1092137A1 (da)
MX (1) MXPA05011860A (da)
NZ (1) NZ543416A (da)
PT (1) PT1622908E (da)
SI (1) SI1622908T1 (da)
WO (1) WO2004106337A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101198608B (zh) * 2005-06-16 2011-04-27 吉利德帕洛阿尔托股份有限公司 A2b腺苷受体拮抗剂的前药
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2274712B1 (es) 2005-10-06 2008-03-01 Laboratorios Almirall S.A. Nuevos derivados imidazopiridina.
JP2009528389A (ja) * 2006-03-02 2009-08-06 シーブイ・セラピューティクス・インコーポレイテッド Ａ２ａアデノシン受容体拮抗剤
WO2009088518A1 (en) * 2008-01-11 2009-07-16 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for the treatment of cancer
US8871751B2 (en) 2008-01-18 2014-10-28 The Board Of Trustees Of The University Of Illinois Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer
JP5460690B2 (ja) * 2008-03-26 2014-04-02 アドヴィナス・セラピューティックス・リミテッド アデノシンレセプターアンタゴニストとしてのヘテロ環化合物
WO2009157938A1 (en) * 2008-06-26 2009-12-30 Cv Therapeutics, Inc. A2b adenosine receptor antagonists for treating cancer
WO2010103547A2 (en) 2009-03-13 2010-09-16 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
WO2011055391A1 (en) 2009-11-09 2011-05-12 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds, its preparation and uses thereof
AU2011303420B2 (en) * 2010-09-13 2014-03-20 Impetis Biosciences Ltd. Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications
JP6360149B2 (ja) 2013-03-15 2018-07-18 ハイドラ バイオサイエンシズ インコーポレイテッドＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． 置換キサンチンおよびその使用方法
ES2580702B1 (es) 2015-02-25 2017-06-08 Palobiofarma, S.L. Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina
WO2017106352A1 (en) 2015-12-14 2017-06-22 Raze Therapeutics, Inc. Caffeine inhibitors of mthfd2 and uses thereof
PL3618829T3 (pl) * 2017-05-05 2023-11-20 Arcus Biosciences, Inc. Pochodne chinazolinopirydyny do leczenia zaburzeń związanych z nowotworem
CN112218867B (zh) * 2018-03-05 2023-11-21 泰昂治疗公司 腺苷受体拮抗剂及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
DE8817122U1 (da) * 1988-12-22 1993-02-04 Boehringer Ingelheim Kg, 6507 Ingelheim, De
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
WO1995011681A1 (en) * 1993-10-29 1995-05-04 Merck & Co., Inc. Human adenosine receptor antagonists
DE19535504A1 (de) * 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
DE69812070T2 (de) * 1998-04-24 2003-12-11 K U Leuven Res & Dev Leuven Immununterdrückende Effekte von 8 substituierten Xanthinderivaten
US6545002B1 (en) * 1999-06-01 2003-04-08 University Of Virginia Patent Foundation Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
DK1401837T3 (da) * 2001-06-29 2005-11-07 Cv Therapeutics Inc Purinderivater som A2B-adenosinreceptorantagonister
AU2002359365B2 (en) * 2001-11-09 2008-07-10 Gilead Sciences, Inc. A2B adenosine receptor antagonists
US7205403B2 (en) * 2002-02-01 2007-04-17 King Pharmaceuticals Research And Development, Inc. 8-Heteroaryl xanthine adenosine A2B receptor antagonists

Also Published As

Publication number Publication date
ATE403656T1 (de) 2008-08-15
HK1092137A1 (en) 2007-02-02
WO2004106337A1 (en) 2004-12-09
MXPA05011860A (es) 2006-02-17
ES2311759T3 (es) 2009-02-16
CA2524778C (en) 2013-01-29
PT1622908E (pt) 2008-11-14
EP1622908B1 (en) 2008-08-06
CA2524778A1 (en) 2004-12-09
CN100590125C (zh) 2010-02-17
DE60322748D1 (de) 2008-09-18
CN1771250A (zh) 2006-05-10
AU2003249604A1 (en) 2005-01-21
SI1622908T1 (sl) 2008-12-31
CY1108457T1 (el) 2014-04-09
EP1622908A1 (en) 2006-02-08
AU2003249604B2 (en) 2011-06-30
NZ543416A (en) 2009-01-31
JP2006515316A (ja) 2006-05-25

Similar Documents

Publication Publication Date Title
HK1092137A1 (en) Xanthine derivatives as a2b adenosine receptor antagonists
DE602005020127D1 (de) Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors
WO2005105803A3 (en) Purine derivatives as a1 adenosine receptor antagonists
DK2272517T3 (da) Orto-kondenserede pyridin- og pyrimidinderivater (f.eks. puriner) som proteinkinaseinhibitorer
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
NO20052493D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger.
IL183706A0 (en) 2,4(4,6) pyrimidine derivatives
WO2005021548A3 (en) Substituted 8-heteroaryl xanthines
DK2270008T3 (da) 8-Heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-oner som PI-3-kinaseinhibitorer
SMAP200600024A (it) 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosia
AP2005003452A0 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
DK2348023T3 (da) Heteroaryl-substituerede pyrrolo[2,3-b]pyridiner og pyrrolo[2,3-b]pyrimidiner som Janus-kinase-inhibitorer
IS7534A (is) Pýrazóló-pýrimídín anilín efnasambönd, gagnleg sem kínasatálmar
ATE370120T1 (de) Substituierte 2-pyridin-cyclohexan-1,4- diaminderivate
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
ATE360632T1 (de) Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate
DK1499316T3 (da) (1-4-piperidinyl)benzimidazolderivater anvendelige som histamin-H3-antagonister
DE60209251D1 (de) Adenosine a2a receptor antagonisten
ATE432282T1 (de) 2-alkinyl- und 2-alkenyl-pyrazolo-ä4,3-eü -1,2,4- triazolo-ä1,5-cü -pyrimidinadenosin a2a rezeptorantagonisten
ATE538123T1 (de) 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors
DK1711177T3 (da) 1H-thieno-2,3-c-pyrazolderivater, der er egnede som kinase-I-inhibitorer
ATE452892T1 (de) Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate
DK1608653T3 (da) Substituerede 8-perfluoroalkyl-6,7,8,9- tetrahydropyrimido (1,2-a) pyrimidin-4-on derivater
ATE358130T1 (de) Bicyclische (1,2,4ö-triazol adenosin a2a rezeptor antagonisten
NO20045025L (no) Nye forbindelser